If you are starting to get the impression that there is little researchers and innovators cannot do with 3D printing, you are thinking in the right direction—as are so many companies and organizations today like BASF Care Creations and Cell Therapy Research Institute CTIBiotech. This was obvious after their presence at the recent NYSCC Cosmetic Congress where they came together to present research from a collaboration regarding a stunning new method for bioprinting.
BASF and CTIBiotech have been working together to advance further in skin care applications, now coming forth with technology for the bioprinting of tissue to create sebaceous glands.
For two years the companies have been researching 3D tissue models for testing bio-actives that are appropriate for skin care applications, resulting in the following:
“Working with BASF allowed us to validate a powerful technology for human skin care research in very little time. This positions CTIBiotech as a world leader in innovative and even disruptive technologies for human cell-based bioassays, applied to dermo-cosmetics,” said CTIBiotech CEO Dr. Nico Forraz.
- Ex vivo production of physiological sebum in a bioprinted culture
- Regulation of the sebum production with active ingredients
The researchers were able to refine the BASF 3D skin model portfolio further thanks to CTIBiotech’s 3D human sebaceous gland technology, which offers a new way for everyone to study sebaceous glands and how they function—especially in research relevant to skin disorders that may be caused by age or microbial issues or inflammation.
“Compared to current in vitro methods, the 3D models developed by CTIBiotech allow analysis more in touch with human physiology and sebaceous gland metabolism,” said BASF’s project lead Dr. Sabine Pain. “That’s how their technology helps us accelerate the development of innovative and highly reliable ingredients for the skin care market. Our understanding of sebaceous gland metabolism provides the basis for developing and testing advanced cosmetic bio-actives for skincare applications, and in particular skincare products for oily skin.”
CTIBiotech is headquartered in France, and has an intensive focus on specialties in biotechnologies for advancing cancer, stem cell, and tissue engineering research. They also make both in vitro and ex vivo cell models for medical and other research, along with innovative medical devices for cell therapy. BASF is focused on research centered around five segments: chemicals, performance products, functional materials and solutions, agricultural solutions, and oil and gas. This latest collaboration should pave the way for many researchers to move forward into unchartered territory for bioprinting.
“Because of their experience and expertise in developing solutions for the dermo-cosmetics market, BASF understands the benefits of collaborating with tissue engineering experts,” added Professor Colin McGuckin, Chief Scientific Officer and President of CTIBiotech. “The next evolution of the sebaceous gland model will be based on a 3D bio-printing technology that allows us to fully reproduce micro-glands into a full thickness skin model, in vitro.”
What do you think of this news? Let us know your thoughts! Join the discussion of this and other 3D printing topics at 3DPrintBoard.com or share your thoughts below.[Source: BASF]
You May Also Like
In-Q-Tel and 3D Printing, Part 1: What’s In-Q-Tel?
So far, a venture capital company called In-Q-Tel has invested in three startups within the 3D printing and scanning space: Voxel8, Arevo, and Fuel3D. If you don’t recognize the name...
3D Printing News Briefs: January 11, 2020
We’ve got some business news to share with you in today’s 3D Printing News Briefs. For starters, Knust-Godwin has purchased a Sapphire 3D printer from VELO3D. The AMable project has...
Canada: University Researchers 3D Print GlioMesh to Treat Brain Cancer
In the recently published ‘A Drug-Eluting 3D-Printed Mesh (GlioMesh) for Management of Glioblastoma,’ Canadian researchers take on the topic of using 3D printing for better treatment of glioblastoma (GBM) as...
Sintratec Providing 3D Printing Support to Daimler Buses for Service Bases
The commercial vehicles segment of Mercedes-Benz parent company Daimler AG has fully integrated 3D printing into the development process and series production workflow for several of its divisions, such as...
View our broad assortment of in house and third party products.